Rafael M. Couñago

Rafael M. Couñago

SGC UNC

Couñago

Biography

Rafael M. Couñago, PhD, is a Principal Investigator at the Structural Genomics Consortium Chemical Biology Center at the University of North Carolina (SGC-UNC), Chapel Hill. Rafael´s research group at SGC-UNC uses protein biochemistry, structural biology and cell-based assays to illuminate protein function and explore new therapeutic strategies for human diseases. Current research at SGC-UNC is focused on enabling the discovery of new antiviral compounds and realizing SGC´s vision for Target 2035, an open science initiative that aims to create chemical and biological tools for every protein in the human genome with the goal of informing drug discovery (https://www.target2035.net/). Rafael joined SGC-UNC after working as a Principal Investigator at the Center of Medicinal Chemistry at the University of Campinas (UNICAMP), São Paulo, Brazil. Prior to that, Rafael served as Team Leader and CSO at SGC-UNICAMP, and was a post-doctoral researcher at the laboratories of Bostjan Kobe at the University of Queensland, Australia; Kurt Krause at Otago University, New Zealand, and Youssif Shamoo at Rice University, USA. Rafael has a strong track record in recombinant protein production, biochemical and cellular assay development, and structure determination, and has participated in a number of early-stage drug discovery projects in collaboration with both academic and industrial partners

2022

A Target Engagement Assay to Assess Uptake, Potency, and Retention of Antibiotics in Living Bacteria.

Fanti RC, Vasconcelos SNS, Catta-Preta CMC, Sullivan JR, Riboldi GP, Dos Reis CV, Ramos PZ, Edwards AM, Behr MA, Couñago RM

ACS Infect Dis. 2022-7-11 . .doi: 10.1021/acsinfecdis.2c00073

PMID: 35815896

Development of the First Covalent Monopolar Spindle Kinase 1 (MPS1/TTK) Inhibitor.

M Serafim RA, da Silva Santiago A, Schwalm MP, Hu Z, Dos Reis CV, Takarada JE, Mezzomo P, Massirer KB, Kudolo M, Gerstenecker S, Chaikuad A, Zender L, Knapp S, Laufer S, Couñago RM, Gehringer M

J Med Chem. 2022-2-15 . .doi: 10.1021/acs.jmedchem.1c01165

PMID: 35167750

Development of dihydropyrrolopyridinone-based PKN2/PRK2 chemical tools to enable drug discovery.

Scott F, Fala AM, Takarada JE, Ficu MP, Pennicott LE, Reuillon TD, Couñago RM, Massirer KB, Elkins JM, Ward SE

Bioorg Med Chem Lett. 2022-1-29 . 60:128588 .doi: 10.1016/j.bmcl.2022.128588

PMID: 35104640

2021

Hinge Binder Scaffold Hopping Identifies Potent Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CAMKK2) Inhibitor Chemotypes.

Eduful BJ, O'Byrne SN, Temme L, Asquith CRM, Liang Y, Picado A, Pilotte JR, Hossain MA, Wells CI, Zuercher WJ, Catta-Preta CMC, Zonzini Ramos P, Santiago AS, Couñago RM, Langendorf CG, Nay K, Oakhill JS, Pulliam TL, Lin C, Awad D, Willson TM, Frigo DE, Scott JW, Drewry DH

J Med Chem. 2021-7-15 . .doi: 10.1021/acs.jmedchem.0c02274

PMID: 34264658

2020

Structural features and development of an assay platform of the parasite target deoxyhypusine synthase of Brugia malayi and Leishmania major.

Silva SF, Klippel AH, Ramos PZ, Santiago ADS, Valentini SR, Bengtson MH, Massirer KB, Bilsland E, Couñago RM, Zanelli CF

PLoS Negl Trop Dis. 2020-10-12 . 14(10):e0008762 .doi: 10.1371/journal.pntd.0008762

PMID: 33044977

SGC-AAK1-1: A Chemical Probe Targeting AAK1 and BMP2K.

Wells C, Couñago RM, Limas JC, Almeida TL, Cook JG, Drewry DH, Elkins JM, Gileadi O, Kapadia NR, Lorente-Macias A, Pickett JE, Riemen A, Ruela-de-Sousa RR, Willson TM, Zhang C, Zuercher WJ, Zutshi R, Axtman AD

ACS Med Chem Lett. 2020-3-12 . 11(3):340-345 .doi: 10.1021/acsmedchemlett.9b00399

PMID: 32184967

In Depth Analysis of Kinase Cross Screening Data to Identify CAMKK2 Inhibitory Scaffolds.

O'Byrne SN, Scott JW, Pilotte JR, Santiago ADS, Langendorf CG, Oakhill JS, Eduful BJ, Couñago RM, Wells CI, Zuercher WJ, Willson TM, Drewry DH

Molecules. 2020-1-13 . 25(2): .doi: 10.3390/molecules25020325

PMID: 31941153

2019

Binding and structural analyses of potent inhibitors of the human Ca2+/calmodulin dependent protein kinase kinase 2 (CAMKK2) identified from a collection of commercially-available kinase inhibitors.

Profeta GS, Dos Reis CV, Santiago ADS, Godoi PHC, Fala AM, Wells CI, Sartori R, Salmazo APT, Ramos PZ, Massirer KB, Elkins JM, Drewry DH, Gileadi O, Couñago RM

Sci Rep. 2019-11-11 . 9(1):16452 .doi: 10.1038/s41598-019-52795-1

PMID: 31712618

The C-Terminal Domains SnRK2 Box and ABA Box Have a Role in Sugarcane SnRK2s Auto-Activation and Activity.

Righetto GL, Sriranganadane D, Halabelian L, Chiodi CG, Elkins JM, Massirer KB, Gileadi O, Menossi M, Couñago RM

Front Plant Sci. 2019-10-18 . 10:1105 .doi: 10.3389/fpls.2019.01105

PMID: 31620147

Development of Pyridine-based Inhibitors for the Human Vaccinia-related Kinases 1 and 2.

Serafim RAM, de Souza Gama FH, Dutra LA, Dos Reis CV, Vasconcelos SNS, da Silva Santiago A, Takarada JE, Di Pillo F, Azevedo H, Mascarello A, Elkins JM, Massirer KB, Gileadi O, Guimarães CRW, Couñago RM

ACS Med Chem Lett. 2019-9-12 . 10(9):1266-1271 .doi: 10.1021/acsmedchemlett.9b00082

PMID: 31531195